CN116234803A - 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合 - Google Patents

用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合 Download PDF

Info

Publication number
CN116234803A
CN116234803A CN202080097414.4A CN202080097414A CN116234803A CN 116234803 A CN116234803 A CN 116234803A CN 202080097414 A CN202080097414 A CN 202080097414A CN 116234803 A CN116234803 A CN 116234803A
Authority
CN
China
Prior art keywords
substituted
alkyl
substitution
halogen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080097414.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·范
Y·钱
W·何
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accutar Biotechnology Inc
Original Assignee
Accutar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accutar Biotechnology Inc filed Critical Accutar Biotechnology Inc
Publication of CN116234803A publication Critical patent/CN116234803A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080097414.4A 2019-12-23 2020-12-23 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合 Pending CN116234803A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952695P 2019-12-23 2019-12-23
US62/952695 2019-12-23
PCT/US2020/066798 WO2021133886A1 (en) 2019-12-23 2020-12-23 Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
CN116234803A true CN116234803A (zh) 2023-06-06

Family

ID=76575087

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080097414.4A Pending CN116234803A (zh) 2019-12-23 2020-12-23 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合

Country Status (6)

Country Link
US (1) US11642342B2 (https=)
EP (1) EP4081518A4 (https=)
JP (1) JP2023508357A (https=)
CN (1) CN116234803A (https=)
CA (1) CA3161892A1 (https=)
WO (1) WO2021133886A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007920A1 (zh) * 2023-07-06 2025-01-09 海创药业股份有限公司 一种降解雌激素受体的联合用药物及其用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220348595A1 (en) * 2021-04-09 2022-11-03 Endotarget Inc. Compounds and methods for the targeted degradation of estrogen receptors
KR20240053589A (ko) * 2021-07-30 2024-04-24 하이노바 파마슈티컬스 인코포레이티드 이중 기능성 키메라 헤테로 고리 화합물 및 이의 안드로겐 수용체 분해제로서의 용도
WO2023102379A1 (en) * 2021-11-30 2023-06-08 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Combination therapy for cancer treatment
EP4446324A4 (en) * 2021-12-08 2026-05-06 Gluetacs Therapeutics Shanghai Co Ltd Ligand compounds for e3 ubiquitin ligase, protein degraders developed on basis of ligand compounds, and uses thereof
WO2023116835A1 (zh) * 2021-12-24 2023-06-29 苏州开拓药业股份有限公司 一种具有酰亚胺骨架的多蛋白降解剂
CN117229286A (zh) * 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
US20260000676A1 (en) * 2022-07-12 2026-01-01 The Regents Of The University Of Michigan Chroman derivatives as estrogen receptor degraders
CN115724836B (zh) * 2022-11-24 2025-07-04 北京大学 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
CN116751186B (zh) * 2022-12-23 2024-10-18 南京知和医药科技有限公司 一种雌激素受体调节剂的制备及其用途
US20250381179A1 (en) 2024-05-22 2025-12-18 Accutar Biotechnology Inc. Chroman-based compounds for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108495618A (zh) * 2016-07-12 2018-09-04 冰洲石生物科技公司 新的化合物及其用途
CN110291087A (zh) * 2016-12-01 2019-09-27 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
WO2020142227A1 (en) * 2019-01-03 2020-07-09 The Regents Of The University Of Michigan Estrogen receptor protein degraders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010021710A1 (en) 1996-10-28 2001-09-13 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
JP2001306582A (ja) 2000-04-20 2001-11-02 Ge Plastics Japan Ltd 成型品情報の検索システム
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2005524630A (ja) 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
PL2305221T3 (pl) 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
CA2737400C (en) 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
WO2013097773A1 (en) 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
AU2018282901A1 (en) * 2017-06-12 2020-01-16 Syros Pharmaceuticals, Inc. Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2019133864A1 (en) 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
WO2019196812A1 (zh) 2018-04-09 2019-10-17 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
US11667621B2 (en) 2018-06-11 2023-06-06 Stevens Institute Of Technology Antiestrogen compounds
US20220016102A1 (en) 2018-11-21 2022-01-20 Shanghaitech University Er protein regulators and use thereof
SG11202105256QA (en) * 2018-11-21 2021-06-29 Accutar Biotechnology Inc Novel compounds having estrogen receptor alpha degradation activity and uses thereof
KR20220054347A (ko) * 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
EP3835298B1 (en) * 2019-12-12 2024-06-26 Accutar Biotechnology Inc. Novel chroman derivatives having estrogen receptor degradation activity and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108495618A (zh) * 2016-07-12 2018-09-04 冰洲石生物科技公司 新的化合物及其用途
CN110291087A (zh) * 2016-12-01 2019-09-27 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
WO2020142227A1 (en) * 2019-01-03 2020-07-09 The Regents Of The University Of Michigan Estrogen receptor protein degraders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MASSIMO CRISTOFANILLI等: "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): fi nal analysis of the multicentre, double-blind, phase 3 randomised controlled trial", 《HE LANCER ONCOLOGY, ELSEVIER, AMSTERDAM, NL》, 3 March 2016 (2016-03-03), pages 426 - 439 *
MASSIMO CRISTOFANILLI等: "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): fi nal analysis of the multicentre, double-blind, phase 3 randomised controlled trial", 《THE LANCER ONCOLOGY, ELSEVIER, AMSTERDAM, NL》, 3 March 2016 (2016-03-03), pages 426 - 439 *
ROBERT L SUTHERLAND等: "CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease", 《BREAST CANCER RESEARCH》, 31 December 2009 (2009-12-31), pages 112, XP055145540, DOI: 10.1186/bcr2454 *
SIBYLLE LOIBL等: "Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results", 《THE ONCOLOGIST 》, 26 June 2017 (2017-06-26), pages 1028 *
SIBYLLE LOIBL等: "Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results", 《THE ONCOLOGIST》, 26 June 2017 (2017-06-26), pages 1028 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007920A1 (zh) * 2023-07-06 2025-01-09 海创药业股份有限公司 一种降解雌激素受体的联合用药物及其用途

Also Published As

Publication number Publication date
WO2021133886A1 (en) 2021-07-01
JP2023508357A (ja) 2023-03-02
EP4081518A4 (en) 2023-12-27
US20210213012A1 (en) 2021-07-15
US11642342B2 (en) 2023-05-09
EP4081518A1 (en) 2022-11-02
CA3161892A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CN116234803A (zh) 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
US20260115297A1 (en) Heterobifunctional compounds as degraders of hpk1
CN111770914B (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
CN102405043B (zh) 前神经原性化合物
US20210261538A1 (en) Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
JP2019536820A (ja) Ｂｒａｄ４およびｊａｋ２の二重阻害剤としての縮合環式ピリミジン化合物、ならびにその使用に関する方法
JP2021502388A (ja) Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
CN112004802A (zh) 作为神经元组胺受体-3拮抗剂的化合物及其用途
TW200936140A (en) Substituted arylamide oxazepinopyrimidone derivatives
EA019033B1 (ru) Ингибиторы дезацетилазы в, основанные на гидроксамате
CN113498352A (zh) 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
US20230257366A1 (en) Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof
JP2022530630A (ja) ＧｌｙＴ１阻害剤の固体形態
US20240197678A1 (en) Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1) and uses thereof
US10519136B2 (en) Dual inhibitors of PARP1 and CDK
CN116113406B (zh) Gas41抑制剂及其使用方法
JP2015534990A (ja) 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
CN114105977A (zh) 雌激素受体调节剂化合物及其用途
CN114828856B (zh) 以稠合嘧啶化合物为有效成分的治疗剂
RU2847441C1 (ru) Серосодержащее производное изоиндолина, способ его получения и его медицинское применение
CN113226321A (zh) 吡唑基化合物及其使用方法
HK40029219B (en) Compounds as neurokinin-1 receptor antagonists and uses thereof
WO2025237418A1 (zh) 一种cdk2抑制剂的盐、晶型及其制备方法和应用
HK40029219A (en) Compounds as neurokinin-1 receptor antagonists and uses thereof
EP4065107A1 (en) New compounds for treatment of diseases related to dux4 expression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination